Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
- Conditions
- Chronic Myeloid Leukemia
- Registration Number
- NCT00302016
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (59)
University of South Alabama Cancer Research Institute
🇺🇸Mobile, Alabama, United States
Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
Antelope Valley Cancer Center
🇺🇸Lancaster, California, United States
Stanford University
🇺🇸Palo Alto, California, United States
University of Colorado
🇺🇸Aurora, Colorado, United States
Rocky Mountain Cancer Center
🇺🇸Denver, Colorado, United States
Georgetown University Medical Center-Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
Washington Cancer Institute
🇺🇸Washington, District of Columbia, United States
Osler Medical Inc./Osler Clinical Research
🇺🇸Melbourne, Florida, United States
Scroll for more (49 remaining)University of South Alabama Cancer Research Institute🇺🇸Mobile, Alabama, United States